Chiome Bioscience Inc. (4583) AI Stock Analysis

• Market Cap: ¥7.78B
• Dividend Yield: N/A
• Average Volume (3M): 521.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: 25.28%
• EPS Growth: 39.15%
• Country: JP
• Employees: 47
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 69,453,800
• 10 Day Avg. Volume: 796,530
• 30 Day Avg. Volume: 521,303
• PEG Ratio: 0.42
• Price to Book (P/B): 6.47
• Price to Sales (P/S): 12.25
• P/FCF Ratio: -7.44
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: ¥113.00 ▲(6.60% Upside)
• Action: Reiterated Date: 02/21/26
• Date: Action: Reiterated 02/21/26

The score is constrained primarily by weak financial performance—persistent large losses and ongoing cash burn—despite modest leverage. Technicals are neutral-to-slightly constructive near term but remain below longer-term averages, and valuation is limited by negative earnings (negative P/E) with no dividend yield data.

Positive Factors

Solid gross margins

Sustained gross margins near 55–60% indicate the company’s core R&D and platform economics can retain value per project. This margin buffer supports reinvestment in discovery and gives more runway per revenue dollar from licensing or collaborations, aiding long-term scalability.

Low financial leverage

Relatively low debt levels reduce near-term solvency risk and interest burden, preserving flexibility to fund programs via partnerships or equity. Modest leverage means the firm can pursue R&D without heavy fixed financing costs, a durable structural advantage in biotech.

Licensing / collaborative R&D model

A business model focused on monetizing R&D via licensing and collaborations aligns incentives with partners and can provide non-dilutive funding and milestone receipts. This model scales without needing commercial infrastructure and suits long lead-times in drug development.

Negative Factors

Persistent cash burn

Sustained negative operating and free cash flow shows accounting losses translate into real cash outflows, depleting runway and raising near-term financing needs. Over a multi-month horizon this increases dilution risk and can force program slowdowns or reprioritization.

Deep unprofitability

Very large negative margins signal the company is far from self-sustaining and reliant on external funding. Persistent losses erode retained equity and constrain the ability to invest across pipelines without frequent capital raises, limiting long-term strategic optionality.

Revenue decline and volatility

Material revenue volatility and a recent ~23% decline undermine predictability of milestone or license receipts. For a company dependent on episodic partner payments, uneven top-line inflows complicate cash planning and heighten execution and funding risk over the next several months.

Chiome Bioscience Inc. Business Overview & Revenue Model

Company Description

Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. The company operates through two segments, Drug Discovery Business and Drug Discovery Support Business. It offers ADLib System, a monoclonal antibody generating system for drug discovery and development; and Human ADLib System, a chicken antibody gene converted to humanized antibodies. The company also provides protein expression and purification services; stable cell line generation services for recombinant protein and antibody production; and antibody generation services using the ADLib system or B cell cloning techniques. Its product pipeline comprises ADCT-701, an anti-dlk1 antibody for treating liver cancer which is under phase 1 trial; CBA-1205, an afucosylated anti-dlk1 antibody for liver cancer, lung cancer, and neuroblastoma which is under phase 1 trial; and CBA-1535, an anti 5T4/WAIF1 antibody for malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and breast cancer (TNBC) which is under phase 1 trial. The company's product pipeline under preclinical study includes LIV-2008/2008b, an anti-TROP-2 antibody for the treatment of TNBC, lung cancer, and colorectal cancer; BMAA, an anti-semphorin3a antibody for treating central, immune/ inflammatory diseases, neurological disorder, and ophthalmic diseases; PCDC, an anti- CDCP1 antibody for lung, colorectal, pancreatic, breast, and ovarian tumors; PTRY, an antibody 5T4/CD3/PD-L1 for treating malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, triple negative breast cancer; and PFKR, anti-CX3CR1 antibody for secondary progressive multiple sclerosis. It serves universities, research institutions, and pharmaceutical companies. Chiome Bioscience Inc. was incorporated in 2005 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Chiome Bioscience Inc. generates revenue primarily through the development and commercialization of its therapeutic antibody candidates. The company earns money by licensing its proprietary ADLib system technology to other pharmaceutical companies, enabling them to discover and develop their own antibody products. Additionally, Chiome may receive milestone payments and royalties from partnerships and collaborations with other biotech and pharmaceutical firms. These partnerships often involve co-development agreements where Chiome contributes its expertise in antibody research and development. The company's revenue model is also supported by potential government grants and funding for its research endeavors.

Chiome Bioscience Inc. Financial Statement Overview

Summary

Overall fundamentals are weak: revenue is volatile with a recent decline, the company remains deeply unprofitable with very large net losses versus revenue, and operating/free cash flow are consistently negative (cash burn persists). Balance sheet leverage is modest, but ongoing losses raise risk of continued equity erosion and funding needs.

Income Statement

Revenue has been volatile and recently declined (2025 revenue down ~23% after growth in 2023–2024). While gross margin is consistently solid (~55–60%), operating performance remains deeply unprofitable with very large losses relative to revenue (net margin roughly -131% to -269% across the period). Losses narrowed versus 2020–2022 but worsened again in 2025, highlighting an uneven path toward scale and profitability.

Balance Sheet

Leverage is modest, with debt-to-equity generally low (~0.06–0.25) and total debt relatively small versus equity, which helps financial flexibility. However, equity levels have been volatile (notably lower in 2023 and 2025 versus 2024/2022), and returns on equity are strongly negative where provided, reflecting ongoing losses and potential continued balance-sheet erosion if profitability does not improve.

Cash Flow

Cash generation is weak, with operating cash flow and free cash flow consistently negative (roughly -0.94B to -1.36B) and not showing a sustained improving trend. Cash burn broadly tracks accounting losses (free cash flow to net income ~1.0 in most years), indicating losses are translating into real cash outflows rather than being largely non-cash, which increases funding risk if the trend persists.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	768.88M	593.29M	780.81M	682.46M	630.82M	712.93M
Gross Profit	436.96M	355.58M	432.85M	398.60M	348.86M	422.46M
EBITDA	-985.87M	-976.03M	-1.01B	-1.21B	-1.24B	-1.46B
Net Income	-997.11M	-982.78M	-1.02B	-1.22B	-1.24B	-1.48B
Balance Sheet
Total Assets	1.96B	1.73B	2.47B	1.75B	2.22B	2.34B
Cash, Cash Equivalents and Short-Term Investments	1.47B	1.21B	2.06B	1.33B	1.73B	1.79B
Total Debt	260.50M	261.70M	281.50M	291.00M	184.00M	183.00M
Total Liabilities	443.39M	605.44M	548.55M	593.73M	424.72M	446.39M
Stockholders Equity	1.52B	1.12B	1.92B	1.16B	1.79B	1.89B
Cash Flow
Free Cash Flow	0.00	-976.07M	-1.00B	-1.07B	-1.19B	-1.13B
Operating Cash Flow	0.00	-935.99M	-1.00B	-1.07B	-1.19B	-1.13B
Investing Cash Flow	0.00	-55.46M	0.00	173.00K	0.00	-35.38M
Financing Cash Flow	0.00	133.20M	1.74B	667.30M	1.13B	271.35M

Chiome Bioscience Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 106.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4583, the sentiment is Negative. The current price of 106 is below the 20-day moving average (MA) of 114.15, below the 50-day MA of 112.72, and below the 200-day MA of 130.75, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 46.73 is Neutral, neither overbought nor oversold. The STOCH value of 20.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4583.

Chiome Bioscience Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4570	72 Outperform	¥15.70B	43.15	―	―	12.91%	37.96%
4579	54 Neutral	¥24.63B	87.05	―	―	9.87%	-24.41%
4565	52 Neutral	¥87.42B	-6.96	-9.05%	―	-1.96%	-64.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4588	50 Neutral	¥79.87B	-34.13	―	―	-9.04%	13.09%
4583	47 Neutral	¥7.78B	-7.74	―	―	25.28%	39.15%
4587	46 Neutral	¥185.07B	-49.16	-10.16%	―	-62.47%	-134.06%

Chiome Bioscience Inc. Corporate Events

Chiome Bioscience Outlines FY2025 Results and mAb Development Focus

Chiome Bioscience has released supplementary information on its financial results for the fiscal year ending December 2025, outlining both performance metrics and operational highlights. The materials emphasize its ongoing drive to speed up discovery and development of monoclonal antibody drugs aimed at unmet medical needs, signaling continued strategic focus on its therapeutic pipeline and corporate operations.

The disclosed agenda covers an overview of FY12/25 financial results and key operational developments, along with corporate and pipeline information in an appendix. While specific figures are not detailed in the release excerpt, the structure indicates an intention to communicate progress to stakeholders and reinforce Chiome’s positioning as a specialized player in antibody-based drug development.

The most recent analyst rating on (JP:4583) stock is a Hold with a Yen116.00 price target. To see the full list of analyst forecasts on Chiome Bioscience Inc. stock, see the JP:4583 Stock Forecast page.

Chiome Bioscience Widens Cash Burn as Sales Drop and Outlook Stays Limited

Chiome Bioscience reported a ninth consecutive annual loss for the fiscal year ended December 31, 2025, as net sales fell 24.0% to ¥593 million and net loss narrowed slightly to ¥982 million, with profitability metrics remaining deeply negative. Total assets and net assets declined significantly, cash and cash equivalents nearly halved, and the company maintained its no-dividend policy, while only issuing a limited 2026 forecast covering ¥600 million in sales for its Drug Discovery Support business, reflecting ongoing uncertainty in its core Drug Discovery and Development segment.

Operating cash outflows remained substantial at ¥935 million despite modest financing inflows, highlighting continued funding needs to sustain R&D and operations. The weaker balance sheet and constrained outlook underscore execution risk in advancing its drug pipeline and could heighten investor focus on Chiome’s ability to secure future partnerships or capital as it navigates a competitive biotech environment.

The most recent analyst rating on (JP:4583) stock is a Hold with a Yen116.00 price target. To see the full list of analyst forecasts on Chiome Bioscience Inc. stock, see the JP:4583 Stock Forecast page.